Clinical Trial Update: A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase II study of PX-866 in recurrent or metastatic castration-resistant prostate cancer has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• PX-866 (PX-866)

Snippet

Sponsor: NCIC Clinical Trials Group | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-05-22